---
title: "Vista Pharmaceuticals Ltd (524711) — Share Price, Financials & Analysis"
symbol: "524711"
company: "Vista Pharmaceuticals Ltd"
canonical: "https://tapetide.com/stocks/524711"
isin: "INE427C01021"
nse_symbol: "VISTAPHARMACEUTICALSLTD"
bse_code: "524711"
sector: "Healthcare"
industry: "Pharmaceuticals"
market_cap_cr: 35.12
generated_at: "2026-09-13T20:16:07.135Z"
---

# Vista Pharmaceuticals Ltd (524711)

Canonical page: https://tapetide.com/stocks/524711

## Company

- **NSE Symbol:** VISTAPHARMACEUTICALSLTD
- **BSE Code:** 524711
- **ISIN:** INE427C01021
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Face Value:** ₹2
- **F&O Eligible:** No
- **Website:** vistapharmaceuticals.com

## About

Incorporated in 1992, Vista Pharmaceuticals 
Ltd manufactures and sells pharmaceutical, medical and veterinary preparations[1]

## Latest Price

## Key Fundamentals

Observed at 2026-09-11T04:51:49.329785Z.

- **Market Cap:** ₹35.12 Cr
- **Classification:** Microcap
- **P/E (reported):** -2.9
- **EPS (TTM):** ₹-1.91
- **EPS (reported):** ₹0
- **Book Value:** ₹5.92
- **Price to Book:** 0.95
- **Dividend Yield:** 0%
- **ROE:** -10.23%
- **ROCE:** -9.03%
- **Debt to Equity:** 0.28
- **Revenue (yearly):** ₹5.4 Cr
- **Net Income:** ₹-16.15 Cr
- **EBITDA:** ₹-14.62 Cr
- **52-Week High:** ₹10.75
- **52-Week Low:** ₹5.5
- **RSI (14):** 38.42

## Tapetide Score

- **Score:** 30 / 100
- **Score date:** 2026-09-04
- **Archetype:** Weak and Under Pressure
- **What it means:** Weak financials are the defining feature, and neither the valuation nor the trend reading is strong enough to offset them. Worth reading the risk flags and recent filings closely before anything else.
- **Pillar profile:** Quality: Weak · Valuation: Expensive · Momentum: Falling
- **Percentile:** 2 (of 4473 scored stocks)
- **Confidence:** 91%
- **Data coverage:** 81%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 23.63 | 9% |
| growth | 1.62 | 9% |
| momentum | 34.24 | 12% |
| ownership | 50 | 24% |
| quality | 6.06 | 22% |
| valuation | 42.79 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Strengths

- Stock is trading at 0.97 times its book value
- Debtor days have improved from 347 to 21.6 days.

### Weaknesses

- Company has low interest coverage ratio.
- Promoter holding is low: 21.2%
- Company has a low return on equity of -17.1% over last 3 years.
- Promoter holding has decreased over last 3 years: -9.29%

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | -42.16% | -308.19% | -3.41% |
| ebitda margin growth | 88.57% | 649.09% | 810.55% | 30.01% |
| net income growth | 83.05% | 251.09% | 258.89% | — |
| revenue growth | 0% | -48.57% | 75% | 34% |
| roce | — | -0.77% | -18.79% | -7.74% |
| roe | — | -8.25% | -12.27% | 67.16% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 3.47 | 1.7 | 3.13 | 1.8 | 2.49 | 2.56 | 3.23 | 1.52 | 1.46 | 2.42 | 0 | 0 |
| Expenses | 4.64 | 3.44 | 2.87 | 2.58 | 3.32 | 4.08 | 4.14 | 2.63 | 4.89 | 5.42 | 7.06 | 0.84 |
| Operating Profit | -1.17 | -1.74 | 0.26 | -0.78 | -0.83 | -1.52 | -0.91 | -1.11 | -3.43 | -3 | -7.06 | -0.84 |
| OPM % | -33.72 | -102.35 | 8.31 | -43.33 | -33.33 | -59.38 | -28.17 | -73.03 | -234.93 | -123.97 | — | — |
| Other Income | 0.08 | 0.02 | 0.1 | 0.07 | 0.01 | 0.12 | 0.24 | 0 | 0.19 | 0.09 | 0.03 | 0.04 |
| Interest | 0.32 | 0.3 | 0.28 | 0.28 | 0.25 | 0.22 | 0.21 | 0.19 | 0.18 | 0.18 | 0.55 | 0.34 |
| Depreciation | 0.18 | 0.18 | 0.18 | 0.18 | 0.18 | 0.19 | 0.18 | 0.18 | 0.2 | 0.19 | 0.19 | 0.19 |
| Profit before tax | -1.59 | -2.2 | -0.1 | -1.17 | -1.25 | -1.81 | -1.06 | -1.48 | -3.62 | -3.28 | -7.77 | -1.33 |
| Tax % | 27.04 | -25.91 | -190 | -26.5 | -22.4 | -26.52 | 40.57 | -12.84 | -28.45 | -29.27 | -24.58 | -25.56 |
| Net Profit | -2.02 | -1.63 | 0.09 | -0.86 | -0.97 | -1.32 | -1.5 | -1.29 | -2.59 | -2.32 | -5.86 | -0.99 |
| EPS in Rs | -0.55 | -0.44 | 0.02 | -0.23 | -0.26 | -0.36 | -0.41 | -0.21 | -0.42 | -0.38 | -0.95 | -0.16 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 29 | 31 | 23 | 1 | 0 | 1 | 10 | 10 | 5 | 4 |
| Expenses | 24 | 30 | 28 | 3 | 2 | 5 | 13 | 14 | 20 | 18 |
| Operating Profit | 5 | 1 | -5 | -2 | -1 | -4 | -3 | -4 | -15 | -14 |
| OPM % | 18 | 4 | -21 | -136 | -326 | -432 | -33 | -41 | -271 | -369 |
| Other Income | 0 | 3 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 3 | 1 | -4 | -4 | -3 | -6 | -5 | -5 | -16 | -16 |
| Tax % | 23 | 18 | -7 | -47 | -66 | -4 | -13 | -12 | -25 | — |
| Net Profit | 2 | 1 | -4 | -2 | -1 | -6 | -5 | -5 | -12 | -12 |
| EPS in Rs | 0.75 | 0.31 | -1.21 | -0.55 | -0.24 | -1.54 | -1.23 | -1.26 | -1.96 | -1.91 |
| Dividend Payout % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 5 | 6 | 6 | 6 | 7 | 7 | 8 | 9 | 12 | 12 |
| Reserves | 11 | 26 | 30 | 24 | 25 | 28 | 29 | 31 | 33 | 24 |
| Borrowings | 11 | 11 | 11 | 15 | 11 | 13 | 10 | 8 | 7 | 10 |
| Other Liabilities | 14 | 10 | 6 | 6 | 9 | 8 | 9 | 10 | 7 | 9 |
| Total Liabilities | 42 | 53 | 53 | 51 | 53 | 56 | 56 | 58 | 60 | 55 |
| Fixed Assets | 13 | 18 | 21 | 21 | 20 | 19 | 20 | 19 | 19 | 18 |
| CWIP | 2 | 7 | 9 | 9 | 9 | 9 | 9 | 10 | 10 | 11 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 26 | 28 | 24 | 22 | 24 | 27 | 27 | 29 | 31 | 26 |
| Total Assets | 42 | 53 | 53 | 51 | 53 | 56 | 56 | 58 | 60 | 55 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 3 | -5 | 3 | 1 | -7 | -1 | -2 | -5 | -7 | -4 |
| Cash from Investing Activity | -4 | -11 | -6 | -2 | 0 | 0 | -1 | -1 | 0 | -1 |
| Cash from Financing Activity | 6 | 11 | 1 | 0 | 7 | 1 | 3 | 6 | 8 | 5 |
| Net Cash Flow | 5 | -4 | -1 | -1 | 0 | 0 | 0 | 0 | 1 | -1 |
| Free Cash Flow | -1 | -15 | -2 | -1 | -7 | -1 | -3 | -6 | -7 | -5 |
| CFO/OP | 84 | -86 | 299 | -17 | 390 | 78 | 64 | 149 | 163 | 30 |

### Ratios

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 136 | 137 | 98 | 165 | 624 | 9789 | 4106 | 515 | 505 | 22 |
| Inventory Days | 185 | 250 | 162 | 148 | 4840 | 9204 | 991 | 279 | 359 | 770 |
| Days Payable | 293 | 209 | 76 | 79 | 2555 | 5297 | 1007 | 304 | 244 | 443 |
| Cash Conversion Cycle | 27 | 178 | 184 | 234 | 2909 | 13696 | 4089 | 490 | 620 | 349 |
| Working Capital Days | 12 | 137 | 137 | 81 | 1681 | 10154 | 3460 | 318 | 440 | -95 |
| ROCE % | 9 | 12 | 6 | -5 | -5 | -4 | -10 | -8 | -9 | -30 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 29.51% | 27.81% | 27.81% | 21.19% | 21.19% | 21.19% | 21.19% | 21.19% | 21.19% | 21.19% | 21.19% | 21.19% |
| FIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| DIIs | 0.03% | 0.03% | 0.03% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 37.28% | 35.43% | 35.43% | 33.44% | 33.86% | 34% | 33.62% | 33.62% | 33.64% | 33.63% | 33.63% | 33.63% |
| Others | 33.18% | 36.74% | 36.74% | 45.36% | 44.93% | 44.79% | 45.17% | 45.17% | 45.16% | 45.16% | 45.17% | 45.17% |
| No. of Shareholders | 14250 | 13908 | 14015 | 13882 | 13913 | 14086 | 14158 | 14061 | 14012 | 14080 | 14154 | 14154 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Sell
- **Buy / Neutral / Sell:** 2 / 5 / 12

### Moving Averages — summary: **Strong Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 5.99 | Sell |
| EMA (10) | 5.95 | Sell |
| SMA (20) | 6.17 | Sell |
| EMA (20) | 6.16 | Sell |
| SMA (50) | 6.67 | Sell |
| EMA (50) | 6.55 | Sell |
| SMA (100) | 7.1 | Sell |
| EMA (100) | 6.92 | Sell |
| SMA (200) | 7.39 | Sell |
| EMA (200) | 7.55 | Sell |

### Oscillators — summary: **Neutral**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 39.1 | Neutral |
| MACD (12,26,9) | -0.26 | Sell |
| Stochastic (14,3,3) | 13.76 | Buy |
| ADX (14) | 23.58 | Neutral |
| Williams %R (14) | -85.12 | Buy |
| ATR (14) | 0.56 | High Volatility |
| ROC (12) | -4.64 | Sell |
| Stoch RSI (14) | 27.39 | Neutral |
| UO (7,14,28) | 45.02 | Neutral |

## Filings & Documents

### Other Documents

| Date | Document |
| --- | --- |
| 5 Feb - Transcript of Investor Conference Call on the Unaudited Financial Results for the quarter and nine months ended December 31, 2025 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript 5 Feb - Transcript of Investor Conference Call on the Unaudited Financial Results for the quarter and nine months ended December 31, 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/c4dcef78-f5ac-4ff4-90b3-74a23fb71250.pdf) |
| 5 Feb - Board meeting on 13-Feb-2026 to approve Q3/9M unaudited results and limited review for 31-12-2025. | [Board Meeting Intimation for 1. Unaudited Financial Results For The Quarter And Nine Months Ended 31.12.2025. 2. Limited Review Report Quarter And Nine Months 31.12.2025. 3. Any Other Business With The Permission Of The Chair. 5 Feb - Board meeting on 13-Feb-2026 to approve Q3/9M unaudited results and limited review for 31-12-2025.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/36eb73a7-4625-4f2c-a19f-07ec652f8850.pdf) |
| 5 Feb - Board meeting on 13 Feb 2026 to consider unaudited results and limited review for quarter/nine months ended 31.12.2025. | [Update on board meeting 5 Feb - Board meeting on 13 Feb 2026 to consider unaudited results and limited review for quarter/nine months ended 31.12.2025.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/4aa4e9eb-f5ef-416c-8359-eb954ff6edfb.pdf) |
| 31 Jan - Newspaper Advertisement pertaining to the Unaudited Financial Results for the quarter and nine months ended December 31, 2025 | [Announcement under Regulation 30 (LODR)-Newspaper Publication 31 Jan - Newspaper Advertisement pertaining to the Unaudited Financial Results for the quarter and nine months ended December 31, 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/4b09a493-e35d-4fe2-9add-fdf2089f6351.pdf) |
| 30 Jan - Q3 & 9M FY26 consolidated: 9M revenue ₹1,722.4cr; Q3 revenue ₹592.2cr; 9M EBITDA ₹301.7cr; 9M PAT ₹181.4cr. | [Announcement under Regulation 30 (LODR)-Press Release / Media Release 30 Jan - Q3 & 9M FY26 consolidated: 9M revenue ₹1,722.4cr; Q3 revenue ₹592.2cr; 9M EBITDA ₹301.7cr; 9M PAT ₹181.4cr.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/3b6820cb-b527-4892-9fd7-a83c28783b22.pdf) |
| 3 Feb - Vista Pharmaceuticals and Pleiades Therapeutics form JV to develop generic and specialty drugs for US and ROW markets. | [Intimation Under Regulation 30 Of SEBI (LODR) Regulations, 2015 - 'Joint Venture Partnership Between Pleiades Therapeutics And Vista Pharmaceuticals Ltd' 3 Feb - Vista Pharmaceuticals and Pleiades Therapeutics form JV to develop generic and specialty drugs for US and ROW markets.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/590dbc51-fd31-45f0-a762-0aff63b91a70.pdf) |
| 29 Apr - Vista Pharmaceuticals confirms it is not a Large Corporate; FY2025-26 borrowing and debt issuance were nil. | [Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2 29 Apr - Vista Pharmaceuticals confirms it is not a Large Corporate; FY2025-26 borrowing and debt issuance were nil.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/875025ec-51aa-49a7-8a2f-26bcd4a209e8.pdf) |
| 29 Apr - Vista Pharmaceuticals confirms it is not a Large Corporate; FY2025-26 borrowing and debt issuance were nil. | [Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2 29 Apr - Vista Pharmaceuticals confirms it is not a Large Corporate; FY2025-26 borrowing and debt issuance were nil.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/875025ec-51aa-49a7-8a2f-26bcd4a209e8.pdf) |
| 27 Mar - Vista Pharmaceuticals: trading window closed from 1 April 2026 until 48 hours after audited results for year/quarter ending 31.03.2026. | [Closure of Trading Window 27 Mar - Vista Pharmaceuticals: trading window closed from 1 April 2026 until 48 hours after audited results for year/quarter ending 31.03.2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/72586db0-c892-427c-801a-4ae513b430f6.pdf) |
| 2 Feb - Investor/analyst conference call audio for Q3 and 9M FY2026 results uploaded (link) Feb 2, 2026. | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 2 Feb - Investor/analyst conference call audio for Q3 and 9M FY2026 results uploaded (link) Feb 2, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/b365f014-4a84-4ac8-b631-dc0886619798.pdf) |

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-08-14 | [Board Meeting Outcome for Results For The Quarter Ended 30.06.2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0db87a7d-98c2-40e0-978f-3fd5f80433fa.pdf) |
| 2026-08-13 | [Board Meeting Intimation for Approval Of Un Audited Financials Results For The Quarter Ended 30.06.2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=cc1d0c8c-0a06-4610-a5b6-c0dd3e0b4cb5.pdf) |
| 2026-07-15 | [Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=66d7a7ff-3a37-4f4a-afc8-fb8373dbd2d9.pdf) |
| 2026-06-25 | [Closure of Trading Window](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c04fafd4-35b3-4efb-ba0a-a9ecb8269adc.pdf) |
| 2026-05-29 | [Compliances-Reg.24(A)-Annual Secretarial Compliance](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6a312c93-372d-4642-aaca-c5a66bca513e.pdf) |
| 2026-05-19 | [Board Meeting Intimation for Approval Of Audited Financial Results For The Quarter And Year Ended 31.03.2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2d931eec-7c2c-4053-a903-dc148d55e156.pdf) |
| 2026-04-29 | [Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=875025ec-51aa-49a7-8a2f-26bcd4a209e8.pdf) |
| 2026-04-14 | [Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d9f6a1e2-2561-480a-b27b-0956a951ae87.pdf) |
| 2026-03-27 | [Closure of Trading Window](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=72586db0-c892-427c-801a-4ae513b430f6.pdf) |
| 2026-02-13 | [Board Meeting Outcome for Un Audited Financial Results For The Quarter Ended 31.12.2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=eeff43cc-7fa1-4296-96d0-a961db269683.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-08-14 | [Results For The Quarter Ended 30.06.2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=bc584684-1607-4dcd-974f-76fe3922fb4d.pdf) |
| 2026-05-29 | [Outcome Of Board Meeting Under Regulations 30 Read With 33 (3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1f370bf7-15fd-4716-bb14-f8d35f9d17a8.pdf) |
| 2026-02-13 | [Results For The Quarter Ended 31.12.2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ac286d05-c170-4a55-947f-542436f9fd60.pdf) |
| 2025-11-13 | [Un Audited Financials Results For The Quarter And Half Year Ended 30.09.2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=16584890-1096-47e1-8a24-ff0a3a66ad0f.pdf) |
| 2025-08-13 | [Results - Unaudited Financial Results For The Quarter Ended 30.06.2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7dd2ef06-bee1-4035-9f27-24c75e5bd4de.pdf) |
| 2025-05-30 | [Outcome Of Board Meeting Under Regulations 30 Read With 33 (3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=04a2c9b5-e665-45ff-8178-d3a8cbe99498.pdf) |
| 2025-02-12 | [Results For The Quarter And Nine Months Ended 31.12.2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fc90c208-cf7d-4946-be6c-863782cd1d3c.pdf) |
| 2024-11-13 | [Outcome Of Board Meeting Under Regulations 30 Read With 33 (3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c1098abf-addb-4ac2-af4e-55300a0f5c8b.pdf) |
| 2024-08-13 | [Outcome Of Board Meeting Under Regulations 30 Read With 33 (3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5e57439c-c9af-4584-a8e8-f60ba1de450c.pdf) |
| 2024-05-28 | [Outcome Of Board Meeting Under Regulations 30 Read With 33 (3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ff4caad6-1fd4-4938-ae97-1f08217a7ab8.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Nov 2025 | [Concall - Nov 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/c191ca8d-d050-4a99-81ed-e77d7a0061da.pdf) |
| May 2025 | [Concall - May 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/a8f49290-8aa1-443a-9e4a-57b718f19adf.pdf) |
| May 2024 | [Concall - May 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/7ef8cdaf-305a-4dd1-ab1d-5af84ea5337a.pdf) |
| Feb 2025 | [Concall - Feb 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/ff6f4019-9ef3-42e8-84ec-123d6705fa40.pdf) |
| Feb 2024 | [Concall - Feb 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/3e85f70a-e718-4561-be27-8e429eb4f6ab.pdf) |
| Aug 2025 | [Concall - Aug 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/83b5530c-1980-4e76-8716-8188288ceecf.pdf) |
| Aug 2025 | [Concall - Aug 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/7f1ad5f3-3550-45c0-9e5f-87428ad54ebb.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from bse | [Financial Year 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/31a187d8-f07a-43a1-a71f-a5b73374b665.pdf) |
| from bse | [Annual Report 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/f6f149d3-442b-4019-9c1e-63f3b5e6bcdb.pdf) |
| from bse | [Financial Year 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/be63b124-39bf-4f32-ace8-9059403c42e2.pdf) |
| from bse | [Annual Report 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/0a3b3a68-7d04-4ff2-962b-a0d030974a54.pdf) |
| from bse | [Annual Report 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/962fe098-781c-4b5e-85ff-fb62c26ab7a6.pdf) |
| from bse | [Annual Report 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/524711/76947524711.pdf) |
| from bse | [Annual Report 2021 from bse](https://www.bseindia.com/bseplus/AnnualReport/524711/70686524711.pdf) |
| from bse | [Annual Report 2020 from bse](https://www.bseindia.com/bseplus/AnnualReport/524711/68105524711.pdf) |
| from bse | [Annual Report 2019 from bse](https://www.bseindia.com/bseplus/AnnualReport/524711/5247110319.pdf) |
| from bse | [Annual Report 2018 from bse](https://www.bseindia.com/bseplus/AnnualReport/524711/5247110318.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T20:16:07.135Z.